Cervical Adenosarcoma – Case Presentation with Successful Conservative Management

Dino Pavoković; Mario Cenkovčan; Vesna Ćosić

doi:10.26332/4xbd6c95

Authors

Dino Pavoković Department of Gynecology and Obstetrics, General Hospital Virovitica, Croatia Author
Mario Cenkovčan Department of Gynecology and Obstetrics, General Hospital Virovitica, Croatia Author
Vesna Ćosić Faculty of Dental Medicine and Health, Josip Juraj Strossmayer University of Osijek; Poliklinika Ćosić d.o.o., Slavonski Brod, Croatia Author

DOI:

https://doi.org/10.26332/4xbd6c95

Keywords:

uterine sarcoma, adenosarcoma, cervix, gynaecologic neoplasm, polyp, abnormal uterine bleeding

Abstract

Adenosarcoma is considered one of the rarest malignancies of female genital system accounting for only about 0.2% of all uterine neoplasms. Due to this rare occurrence, there is a limited amount of data relevant to the treatment and observation of this malignant uterine tumour. Although the treatment in this situation is a total hysterectomy and bilateral salpingo-oophorectomy, it is possible to perform a localized tumour excision if the patient wishes to preserve fertility. It is of paramount importance to monitor the patient due to high recurrence of this tumour despite its most common presentation in a localized stage through abnormal uterine bleeding. In this paper, we present a case of a 34-year-old patient who was admitted because of an abnormal uterine bleeding. Ultrasound evaluation confirmed that there was an endocervical polyp. A localized adenosarcoma was histologically confirmed by endocervical polyp ablation. Regular endometrial and endocervical biopsies have not found any tumor cells and the patient spontaneously conceived and successfully delivered two pregnancies. This case is worth presenting because of its rarity and limited amount of existing data and research on the subject.

References

1. Nathenson MJ, Ravi V, Fleming N, Wang WL, Conley A. Uterine Adenosarcoma: a Review. Curr Oncol Rep. 2016;18(11):68.

2. D'Angelo E, Prat J. Uterine sarcomas: a review. Gynecol Oncol. 2010;116(1):131-9.

3. Clement PB, Scully RE. Mullerian adenosarcoma of the uterus: a clinicopathologic analysis of 100 cases with a review of the literature. Hum Pathol. 1990;21(4):363-81.

4. Kaku T, Silverberg SG, Major FJ, Miller A, Fetter B, Brady MF. Adenosarcoma of the uterus: a Gynecologic Oncology Group clinicopathologic study of 31 cases. Int J Gynecol Pathol. 1992;11(2):75-88.

5. Arend R, Bagaria M, Lewin SN, Sun X, Deutsch I, Burke WM, et al. Long-term outcome and natural history of uterine adenosarcomas. Gynecol Oncol. 2010;119(2):305-8.

6. Gallardo A, Prat J. Mullerian adenosarcoma: a clinicopathologic and immunohistochemical study of 55 cases challenging the existence of adenofibroma. Am J Surg Pathol. 2009;33(2):278-88.

7. Verschraegen CF, Vasuratna A, Edwards C, Freedman R, Kudelka AP, Tornos C, et al. Clinicopathologic analysis of mullerian adenosarcoma: the M.D. Anderson Cancer Center experience. Oncol Rep. 1998;5(4):939-44.

8. Huang GS, Arend RC, Sakaris A, Hebert TM, Goldberg GL. Extragenital adenosarcoma: a case report, review of the literature, and management discussion. Gynecol Oncol. 2009;115(3):472-5.

9. Kondi-Pafiti A, Spanidou-Carvouni H, Papadias K, Hatzistamou-Kiari I, Kontogianni K, Liapis A, et al. Malignant neoplasms arising in endometriosis: clinicopathological study of 14 cases. Clin Exp Obstet Gynecol. 2004;31(4):302-4.

10. Press MF, Scully RE. Endometrial "sarcomas" complicating ovarian thecoma, polycystic ovarian disease and estrogen therapy. Gynecol Oncol. 1985;21(2):135-54.

11. Akhavan A, Akhavan Tafti M, Aghili F, Navabii H. Uterine adenosarcoma in a patient with history of breast cancer and long-term tamoxifen consumption. BMJ Case Rep. 2012;2012.

12. Carroll A, Ramirez PT, Westin SN, Soliman PT, Munsell MF, Nick AM, et al. Uterine adenosarcoma: an analysis on management, outcomes, and risk factors for recurrence. Gynecol Oncol. 2014;135(3):455-61.

13. Eichhorn JH, Young RH, Clement PB, Scully RE. Mesodermal (müllerian) adenosarcoma of the ovary: a clinicopathologic analysis of 40 cases and a review of the literature. Am J Surg Pathol. 2002;26(10):1243-58.

14. Alkilani YG, Apodaca-Ramos I. Cervical Polyps. StatPearls. Treasure Island (FL)2022.

15. Oh H, Park SB, Park HJ, Lee ES, Hur J, Choi W, et al. Ultrasonographic features of uterine cervical lesions. Br J Radiol. 2021;94(1121):20201242.

16. Horn LC, Schmidt D, Fathke C, Ulrich U. [New FIGO staging for uterine sarcomas]. Pathologe. 2009;30(4):302-3.

17. Prat J. FIGO staging for uterine sarcomas. Int J Gynaecol Obstet. 2009;104(3):177-8.

18. Tanner EJ, Toussaint T, Leitao MM, Hensley ML, Soslow RA, Gardner GJ, et al. Management of uterine adenosarcomas with and without sarcomatous overgrowth. Gynecologic oncology. 2013;129(1):140-4.

19. Bernard B, Clarke BA, Malowany JI, McAlpine J, Lee CH, Atenafu EG, et al. Uterine adenosarcomas: a dual-institution update on staging, prognosis and survival. Gynecol Oncol. 2013;131(3):634-9.

20. Brooks SE, Zhan M, Cote T, Baquet CR. Surveillance, epidemiology, and end results analysis of 2677 cases of uterine sarcoma 1989-1999. Gynecol Oncol. 2004;93(1):204-8.

21. McCluggage WG. Mullerian adenosarcoma of the female genital tract. Adv Anat Pathol. 2010;17(2):122-9.

22. Lee Y-J, Kim D-Y, Suh D-S, Kim J-H, Kim Y-M, Kim Y-T, et al. Feasibility of uterine preservation in the management of early-stage uterine adenosarcomas: a single institute experience. World Journal of Surgical Oncology. 2017;15(1):87.

23. Nigro MC, Nannini M, Rizzo A, Pantaleo MA. Current status on treatment of uterine adenosarcoma: updated literature review. Gynecology and Pelvic Medicine. 2021;4.

24. Abeler VM, Røyne O, Thoresen S, Danielsen HE, Nesland JM, Kristensen GB. Uterine sarcomas in Norway. A histopathological and prognostic survey of a total population from 1970 to 2000 including 419 patients. Histopathology. 2009;54(3):355-64.